DK1263729T3 - Cykliske azaforbindelser til anvendelse til behandling af serotoninrealterede sygdomme - Google Patents

Cykliske azaforbindelser til anvendelse til behandling af serotoninrealterede sygdomme

Info

Publication number
DK1263729T3
DK1263729T3 DK01914716T DK01914716T DK1263729T3 DK 1263729 T3 DK1263729 T3 DK 1263729T3 DK 01914716 T DK01914716 T DK 01914716T DK 01914716 T DK01914716 T DK 01914716T DK 1263729 T3 DK1263729 T3 DK 1263729T3
Authority
DK
Denmark
Prior art keywords
treatment
serotonin
related diseases
aza compounds
cyclic aza
Prior art date
Application number
DK01914716T
Other languages
Danish (da)
English (en)
Inventor
Glenn Croston
Carl M Andersson
E L Hansen
A K Uldam
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Application granted granted Critical
Publication of DK1263729T3 publication Critical patent/DK1263729T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK01914716T 2000-03-06 2001-03-06 Cykliske azaforbindelser til anvendelse til behandling af serotoninrealterede sygdomme DK1263729T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18728900P 2000-03-06 2000-03-06
PCT/US2001/007187 WO2001066521A1 (en) 2000-03-06 2001-03-06 Azacyclic compounds for use in the treatment of serotonin related diseases

Publications (1)

Publication Number Publication Date
DK1263729T3 true DK1263729T3 (da) 2007-04-30

Family

ID=22688370

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01914716T DK1263729T3 (da) 2000-03-06 2001-03-06 Cykliske azaforbindelser til anvendelse til behandling af serotoninrealterede sygdomme
DK06026352.2T DK1787984T3 (en) 2000-03-06 2001-03-06 AZACYCLIC COMPOUNDS FOR USING THE TREATMENT OF SEROTON-RELATED DISEASES

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06026352.2T DK1787984T3 (en) 2000-03-06 2001-03-06 AZACYCLIC COMPOUNDS FOR USING THE TREATMENT OF SEROTON-RELATED DISEASES

Country Status (21)

Country Link
US (9) US6815458B2 (de)
EP (1) EP1263729B1 (de)
JP (1) JP4664564B2 (de)
KR (2) KR20080059687A (de)
CN (2) CN1443167B (de)
AT (1) ATE348808T1 (de)
AU (2) AU780006B2 (de)
BR (1) BRPI0108977B8 (de)
CA (1) CA2397981C (de)
CY (1) CY1118651T1 (de)
DE (1) DE60125335T2 (de)
DK (2) DK1263729T3 (de)
ES (1) ES2278729T3 (de)
HK (1) HK1051684A1 (de)
IL (2) IL151164A0 (de)
MX (1) MXPA02008770A (de)
NZ (1) NZ520240A (de)
PT (1) PT1263729E (de)
RU (3) RU2002126554A (de)
WO (1) WO2001066521A1 (de)
ZA (1) ZA200205902B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
IL151164A0 (en) * 2000-03-06 2003-04-10 Acadia Pharm Inc Azacyclic compounds for use in the treatment of serotonin related diseases
EP1318988A2 (de) * 2000-09-11 2003-06-18 Sepracor, Inc. Liganden für monoamin rezeptoren und transporter, und verwendungsmethoden dafür (neurotransmission)
KR20030029978A (ko) * 2000-09-25 2003-04-16 액테리온 파마슈티칼 리미티드 말라리아에 유용한 치환된 아미노-아자-사이클로알칸
US6693099B2 (en) * 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
WO2002102801A1 (en) * 2001-05-23 2002-12-27 Neurosearch A/S Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
MXPA04003103A (es) * 2001-10-02 2004-07-27 Acadia Pharm Inc Derivados de bencimidazolidinona como agentes muscarinicos.
US6951849B2 (en) * 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
KR20100008799A (ko) 2001-12-28 2010-01-26 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
AU2003247615B2 (en) * 2002-06-24 2007-08-09 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
AU2007203444C1 (en) * 2002-06-24 2010-03-11 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
WO2004009549A2 (en) * 2002-07-18 2004-01-29 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
CA2512639C (en) 2003-01-16 2012-10-30 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
EP1622907A1 (de) * 2003-04-30 2006-02-08 Actelion Pharmaceuticals Ltd. Azabicyclononen derivate
WO2005000811A1 (en) * 2003-06-11 2005-01-06 Eli Lilly And Company 3-aminopyrrolidines as inhibitors of monoamine uptake
WO2004110995A1 (en) 2003-06-17 2004-12-23 Pfizer Limited N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
JP2007508260A (ja) * 2003-10-09 2007-04-05 アクテリオン　ファマシューティカルズ　リミテッド 新規なテトラヒドロピリジン誘導体
CA2540782A1 (en) * 2003-10-13 2005-05-06 Olivier Bezencon Diazabicyclononene derivatives and their use as renin inhibitors
DE102004013227A1 (de) * 2004-03-18 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von N-Substituierten 3-Beta-Aminonortropanen
US7321042B2 (en) 2003-10-16 2008-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing N-substituted 3-β-aminonortropanes
JP2007509099A (ja) * 2003-10-23 2007-04-12 アクテリオン　ファマシューティカルズ　リミテッド 新規ジアザビシクロノネンおよび新規極性側鎖を有するテトラヒドロピリジン誘導体
WO2005053663A2 (en) * 2003-11-24 2005-06-16 Eli Lilly And Company Norepinephrine reuptake inhibitors useful for treatment of cognitive failure
US7588733B2 (en) * 2003-12-04 2009-09-15 Idexx Laboratories, Inc. Retaining clip for reagent test slides
CA2547547A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
CA2547551A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives with a new side-chain
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
EP2289879B1 (de) 2004-09-27 2014-11-12 Acadia Pharmaceuticals Inc. Synthese einer Kristallform des Tartratsalzes von n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)Carbamid.
JP2008523136A (ja) * 2004-12-14 2008-07-03 ファイザー・リミテッド セロトニンおよびノルアドレナリン再取り込み阻害剤としてのｎ−ピロリジン−３−イル−アミド誘導体
US20060173037A1 (en) * 2005-01-10 2006-08-03 Nathalie Schlienger Aminophenyl derivatives as selective androgen receptor modulators
WO2007124136A1 (en) * 2006-04-19 2007-11-01 Acadia Pharmaceuticals, Inc. Use of 4-amino-piperidines for treating sleep disorders
US8865737B2 (en) * 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2129378B1 (de) 2007-02-28 2011-06-01 Thromboserin Limited Therapeutische zusammensetzungen enthaltend thromboserin oder dessen salze zur verwendung in der prophylaxe oder behandlung von thrombose in patienten mit blutungsrisiko
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
JP2010540454A (ja) * 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
US20090082342A1 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
AU2009259494A1 (en) * 2008-06-16 2009-12-23 F. Hoffmann-La Roche Ag Heteroaromatic monoamides as orexinin receptor antagonists
WO2010111353A1 (en) * 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2012113103A1 (en) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
WO2014085362A1 (en) 2012-11-27 2014-06-05 Acadia Pharmaceuticals Inc. Methods for the treatment of parkinson's disease psychosis using pimavanserin
KR20160079846A (ko) * 2013-11-27 2016-07-06 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 피페리딘 및 피페라진 유도체, 및 바이러스 감염 및 암 치료에서의 그의 용도
PL3325444T3 (pl) 2015-07-20 2021-12-06 Acadia Pharmaceuticals Inc. Sposoby wytwarzania N-(4-fluorobenzylo)-N-(1-metylopiperydyn-4-ylo)-N'-(4-(2-metylopropyloksy)fenylometylo)karbamidu oraz jego soli winianowej i postaci polimorficznej C
CN105153016B (zh) * 2015-10-12 2017-10-03 北京诺康达医药科技有限公司 一种匹莫范色林的制备方法
CN105906531A (zh) * 2015-12-23 2016-08-31 嘉实（湖南）医药科技有限公司 一种匹莫范色林中间体的制备方法
CN105481757A (zh) * 2015-12-25 2016-04-13 北京康立生医药技术开发有限公司 一种哌马色林的制备方法
CN105523993A (zh) * 2015-12-28 2016-04-27 重庆两江药物研发中心有限公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用
KR102640774B1 (ko) 2016-03-22 2024-02-26 헬신 헬쓰케어 에스.에이. 벤젠술포닐-비대칭 우레아 및 그의 의학적 용도
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (de) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
KR20200043409A (ko) 2017-08-21 2020-04-27 아카디아 파마슈티칼스 인코포레이티드 질병 치료를 위한 화합물, 이의 염 및 방법
EP3672960A2 (de) * 2017-08-21 2020-07-01 Acadia Pharmaceuticals Inc. Verbindungen, salze davon und deren verwendung zur behandlung von krankheiten
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
US10781172B2 (en) 2018-06-21 2020-09-22 Northwestern University Catalysts and methods for enantioselective conjugate additions of amines to unsaturated electrophiles
WO2020092618A1 (en) 2018-10-30 2020-05-07 Acadia Pharmaceuticals Inc. Methods of treating depression, anxiety and sexual dysfunction using the compound primavanserin
CN113214231B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其医疗应用
CN113214141B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其制备和应用
EP4186893A1 (de) * 2020-07-22 2023-05-31 Geneora Pharma (Shijiazhuang) Co., Ltd. 5-ht2a-rezeptorhemmer oder -inversagonist, herstellungsverfahren dafür und anwendung davon
CN114763335A (zh) * 2021-01-15 2022-07-19 江苏谛奇医药科技有限公司 4-酰胺哌啶类衍生物及其制备方法和应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1234567A (en) * 1915-09-14 1917-07-24 Edward J Quigley Soft collar.
BE794333A (fr) 1972-01-20 1973-07-19 Wyeth John & Brother Ltd Composes heterocycliques azotes therapeutiques
GB1507462A (en) * 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
GB1586468A (en) * 1976-10-29 1981-03-18 Anphar Sa Piperidine derivatives
CA1140119A (en) 1978-04-03 1983-01-25 Joseph Torremans N-heterocyclyl-4-piperidinamines
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US4353901A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
GB8621892D0 (en) * 1986-09-11 1986-10-15 Lundbeck & Co As H Organic compound
FR2642069B1 (fr) * 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
US5214055A (en) * 1990-05-18 1993-05-25 Adir Et Compagnie Aminopiperidine 4-oxo-4H-chromen-2-yl compounds
US5216165A (en) * 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
IT1252227B (it) 1991-12-17 1995-06-05 Ciba Geigy Spa Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
JPH09501404A (ja) 1993-05-26 1997-02-10 スミスクライン・ビーチャム・ラボラトワール・ファルマソーティク 新規化合物
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
DE4404183A1 (de) * 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
DE69633245T2 (de) 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation
US5891889A (en) * 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2001519766A (ja) * 1996-04-03 2001-10-23 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼの阻害剤
DE69729583T2 (de) * 1996-04-17 2005-06-09 Bristol-Myers Squibb Pharma Co. N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-on derivative als faktor xa inhibitoren
US5869488A (en) * 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
CA2262818A1 (en) 1996-09-10 1998-03-19 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Modified amino acids, pharmaceuticals containing these compounds and methods for their production
DE19643331A1 (de) 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
BR9808502A (pt) 1997-05-08 2000-05-23 Smithkline Beecham Corp Inibidores de protease
JP2003514763A (ja) 1998-04-14 2003-04-22 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 非内在性の構成的に活性化されるヒトセロトニンレセプターおよびその小分子調節物質
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6358698B1 (en) * 1998-10-07 2002-03-19 Acadia Pharmacueticals Inc. Methods of identifying inverse agonists of the serotonin 2A receptor
WO2000020636A1 (en) * 1998-10-07 2000-04-13 Acadia Pharmaceuticals Inc. Methods of identifying inverse agonists of the serotonin 2a receptor
CA2315050C (en) 1998-10-16 2009-02-03 Suntory Limited Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
US6150393A (en) * 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
EP1013276A1 (de) * 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkane als CCR5-Modulatoren
EP1178800A4 (de) 1999-03-24 2002-07-31 Univ California Verfahren zur Behandlung von Neurodegenerativen Störungen unter Verwendung der Inhibitoren von Aspartyl-Protease
US6399619B1 (en) * 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
CN1356977A (zh) 1999-05-17 2002-07-03 诺沃挪第克公司 胰高血糖素拮抗剂/反向激动剂
US20050148018A1 (en) * 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US7022698B2 (en) * 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
JP3700524B2 (ja) * 2000-03-03 2005-09-28 株式会社村田製作所 多層集合基板および多層セラミック部品の製造方法
IL151164A0 (en) * 2000-03-06 2003-04-10 Acadia Pharm Inc Azacyclic compounds for use in the treatment of serotonin related diseases
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
GB0108099D0 (en) 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
KR20100008799A (ko) * 2001-12-28 2010-01-26 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
EP1509505A2 (de) 2002-01-23 2005-03-02 Arena Pharmaceuticals, Inc. Nicht-endogene, konstitutiv aktivierte rezeptoren für menschliches serotonin und modulatoren von kleiner molekülgrösse
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
AU2003247615B2 (en) * 2002-06-24 2007-08-09 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2004009549A2 (en) 2002-07-18 2004-01-29 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
WO2004039322A2 (en) 2002-10-29 2004-05-13 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
CA2512639C (en) * 2003-01-16 2012-10-30 Acadia Pharmaceuticals Inc. Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
WO2004064753A2 (en) 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
DK1594840T3 (da) 2003-02-17 2007-02-05 Hoffmann La Roche Piperidin-benzensulfonamid-derivater
SI1696931T1 (sl) 2003-12-22 2009-08-31 Acadia Pharm Inc Amino substituirani diaril(a,d)cikloheptenski analogi kot muskarinski agonisti in postopki za zdravljenje nevropsihiatričnih motenj
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
EP2289879B1 (de) * 2004-09-27 2014-11-12 Acadia Pharmaceuticals Inc. Synthese einer Kristallform des Tartratsalzes von n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)Carbamid.
US7732167B2 (en) * 2005-06-17 2010-06-08 Regeneron Pharmaceuticals, Inc. Interferon-α/β binding fusion proteins and therapeutic uses thereof

Also Published As

Publication number Publication date
CN1443167A (zh) 2003-09-17
BRPI0108977B8 (pt) 2021-05-25
CN1443167B (zh) 2012-07-18
WO2001066521A1 (en) 2001-09-13
US20020004513A1 (en) 2002-01-10
ZA200205902B (en) 2003-10-23
CA2397981A1 (en) 2001-09-13
RU2007139896A (ru) 2009-05-10
US20050014757A1 (en) 2005-01-20
KR20080059687A (ko) 2008-06-30
ES2278729T3 (es) 2007-08-16
US6815458B2 (en) 2004-11-09
NZ520240A (en) 2005-04-29
MXPA02008770A (es) 2004-09-10
KR20030011275A (ko) 2003-02-07
EP1263729B1 (de) 2006-12-20
IL151164A (en) 2011-06-30
BRPI0108977B1 (pt) 2016-08-02
JP4664564B2 (ja) 2011-04-06
HK1051684A1 (en) 2003-08-15
RU2002126554A (ru) 2004-03-20
US20150259291A1 (en) 2015-09-17
ATE348808T1 (de) 2007-01-15
US20060194778A1 (en) 2006-08-31
US9296694B2 (en) 2016-03-29
DK1787984T3 (en) 2017-01-30
CN101230034A (zh) 2008-07-30
JP2003531829A (ja) 2003-10-28
CA2397981C (en) 2010-12-21
EP1263729A1 (de) 2002-12-11
US20160237036A1 (en) 2016-08-18
US20090186921A1 (en) 2009-07-23
RU2398765C1 (ru) 2010-09-10
AU2005202257B2 (en) 2009-06-18
IL151164A0 (en) 2003-04-10
AU780006B2 (en) 2005-02-24
AU780006C (en) 2001-09-17
PT1263729E (pt) 2007-03-30
CY1118651T1 (el) 2017-07-12
AU2005202257C1 (en) 2009-10-29
BR0108977A (pt) 2004-01-06
DE60125335T2 (de) 2007-07-12
US9765053B2 (en) 2017-09-19
DE60125335D1 (de) 2007-02-01
US20170165273A9 (en) 2017-06-15
US20110301191A1 (en) 2011-12-08
US20060194834A1 (en) 2006-08-31
AU4007201A (en) 2001-09-17
US6756393B2 (en) 2004-06-29
US20030220316A1 (en) 2003-11-27
AU2005202257A1 (en) 2005-06-16
KR100879647B1 (ko) 2009-01-20

Similar Documents

Publication Publication Date Title
DK1263729T3 (da) Cykliske azaforbindelser til anvendelse til behandling af serotoninrealterede sygdomme
TW200505901A (en) Muscarinic agonists
DE60115842D1 (de) Ventilanordnung
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson&#39;s disease
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE400258T1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DK1030667T3 (da) Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
PT1265904E (pt) Novos moduladores alostericos positivos de receptores ampa (paarm) processo paraa sua preparacao e sua utilizacao como medicamento
GEP201606538B (en) Preoperative treatment of post operative pain
ATE409042T1 (de) Verwendung von sulodexide zur behandlung von diabetischer nephropathie
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
SE0100873D0 (sv) Method of treatment
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
DE60121978D1 (de) 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
ATE370733T1 (de) Pharmazeutische kombinationspräparat zur behandlung von spastischkeit und/oder schmerzen
ATE245151T1 (de) Diphenyl-1,2,3-thiadiazol-3-oxide, zusammensetzungen und verfahren zur anwendung